<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02983253</url>
  </required_header>
  <id_info>
    <org_study_id>ImmunUHEssen</org_study_id>
    <nct_id>NCT02983253</nct_id>
  </id_info>
  <brief_title>Immunmodulation in Patients With HHT</brief_title>
  <official_title>Immunmodulation in Patients With HHT</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Essen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Essen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Hereditary haemorrhagic telangiectasia (HHT), also known as Rendu-Osler-Weber syndrome, is an
      inherited multisystemic disorder. Literature suggests that HHT is often associated with
      higher frequency of infectious diseases.

      The purpose of this study is to evaluate a variety of immunologic parameters in the blood
      serum of HHT patients in comparison to probands.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Hereditary haemorrhagic telangiectasia (HHT), also known as Rendu-Osler-Weber syndrome, is an
      inherited multisystemic disorder with recurrent epistaxis, mucocutaneous telangiectasia and
      visceral arteriovenous malformations. Literature and the investigators' observation suggest
      that HHT is often associated with higher frequency of infectious diseases. This might be a
      hint for a immunocompromised situation.

      The purpose of this study is to evaluate a variety of immunologic parameters in the blood
      serum of HHT patients in comparison to probands.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2016</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">September 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Amounts of leucocytes in patients with HHT</measure>
    <time_frame>November 2016 - December 2018</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Differences in distribution of leucocytes in patients with HHT</measure>
    <time_frame>November 2016 - December 2018</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Functional properties of leucocytes in patients with HHT</measure>
    <time_frame>November 2016 - December 2018</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Differences in size of leucocytes in patients with HHT</measure>
    <time_frame>November 2016 - December 2018</time_frame>
  </other_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Hereditary Haemorrhagic Telangiectasia (HHT)</condition>
  <arm_group>
    <arm_group_label>Patients with HHT</arm_group_label>
    <description>blood sample of patients with HHT</description>
  </arm_group>
  <arm_group>
    <arm_group_label>probands</arm_group_label>
    <description>blood sample of healthy controls</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>blood sample</intervention_name>
    <description>none, only laboratory tests on blood serum</description>
    <arm_group_label>Patients with HHT</arm_group_label>
    <arm_group_label>probands</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      blood sample
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Inclusion Criteria: Aged 18 or over, HHT,
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  aged 18 or over, HHT

        Exclusion Criteria:

          -  Unable to provide informed consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Urban Geisthoff, Prof.Dr.med.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Essen</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Freya Droege, Dr. med.</last_name>
    <phone>0049 201723</phone>
    <phone_ext>2481</phone_ext>
    <email>freya.droege@uk-essen.de</email>
  </overall_contact>
  <location>
    <facility>
      <name>University Hospital Essen</name>
      <address>
        <city>Essen</city>
        <zip>45147</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Freya Droege, Dr. med.</last_name>
      <phone>0049201723</phone>
      <phone_ext>2481</phone_ext>
      <email>freya.droege@uk-essen.de</email>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>December 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 2, 2016</study_first_submitted>
  <study_first_submitted_qc>December 2, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 6, 2016</study_first_posted>
  <last_update_submitted>December 7, 2016</last_update_submitted>
  <last_update_submitted_qc>December 7, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 8, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital, Essen</investigator_affiliation>
    <investigator_full_name>Urban Geisthoff</investigator_full_name>
    <investigator_title>Prof. Dr. med. Urban Geisthoff</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Telangiectasis</mesh_term>
    <mesh_term>Telangiectasia, Hereditary Hemorrhagic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

